Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation
CADTH Optimal Use Project
Warfarin has been the mainstay of oral anticoagulant therapy for more than 60 years. The effectiveness of warfarin for the prevention of stroke in patients with atrial fibrillation is well established. In Canada, an estimated 200,000 to 250,000 people have this condition.
Need for Recommendations
Managing warfarin therapy is challenging because warfarin interacts with many foods and other drugs. Each patient needs an individualized warfarin dose, which takes time to determine and requires patients to go in for frequent laboratory testing of their blood to monitor their international normalized ratio (INR). The effectiveness and safety of warfarin depend on maintaining INR at therapeutic levels — too little warfarin (low INR) puts the patient at risk of stroke or other blood clots, while too much warfarin (high INR) puts the patient at risk of bleeding.
There are different approaches to managing warfarin therapy. Family doctors often follow and adjust the warfarin dose of their patients themselves, but some have the opportunity to refer patients to specialized anticoagulation clinics, where a team of health professionals will manage the warfarin therapy. In other cases, patients are able to self-test their INR and self-manage their warfarin therapy from home. Considering that location and resources can limit these options, there was a need to find out which approach is best. Specifically, the three research questions were:
Question 1: What is the role of specialized anticoagulation services or other anticoagulation management options for the optimal management of warfarin therapy?
Question 2: What is the role of patient self-testing and patient self-management for the optimal management of warfarin therapy?
Question 3: In remote areas, what types of anticoagulation management options can be recommended?
The COMPUS Expert Review Committee provided expert guidance on this project.
CADTH’s work on this project resulted in several key messages.
- Warfarin has been used for more than 60 years and is safe and effective in preventing stroke and other complications in patients with atrial fibrillation, but there’s still room for improvement in how it’s managed.
- Managing warfarin therapy (e.g., INR testing and interpretation, dose adjustments, checking for complications) should follow a structured plan, whether it is taking place in a specialized anticoagulation clinic, a family doctor’s or specialist’s office, or other care setting.
- A structured approach to managing warfarin therapy in any care setting should ensure ongoing patient education and follow-up, make use of dosing tools, and involve caregivers and other health professionals.
- Patient self-testing and self-management of warfarin may be an option for select patients, but is not recommended for most.
For the full recommendations and detailed information on their development, see the Recommendations Report on the reports page.